New combo shows promise for rare blood cancer
NCT ID NCT07385989
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the drug golidocitinib to standard chemotherapy and immunotherapy works better than the standard treatment alone for people with advanced NK/T-cell lymphoma, a rare blood cancer. About 40 adults will be randomly assigned to one of two groups. The main goal is to see if the new combo leads to more complete remissions after 6 cycles of treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTRANODAL NK/T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking thousands of patients unlock the secrets of rare EBV-driven blood cancers?
- Immunotherapy combo may outperform chemo in rare lymphoma
- Engineered donor cells take aim at tough blood cancers in early trial
- Promising combo may slash radiation harm in rare lymphoma
- New hope for deadly lymphoma combo: drug cocktail targets both cancer and immune chaos
- New hope for rare blood cancer: experimental drug IMC-001 tested in 23 patients